Geode Capital Management’s MiNK Therapeutics INKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$235K Buy
18,759
+3,186
+20% +$36.2K ﹤0.01% 3819
2026
Q2
$182K Sell
15,573
-1,772
-10% -$20.6K ﹤0.01% 3947
2026
Q1
$183K Buy
17,345
+3,098
+22% +$34.5K ﹤0.01% 3939
2025
Q4
$159K Buy
14,247
+1,441
+11% +$18.6K ﹤0.01% 3985
2025
Q3
$179K Buy
12,806
+1,314
+11% +$21K ﹤0.01% 3962
2025
Q2
$86K Buy
11,492
+238
+2% +$1.79K ﹤0.01% 4102
2025
Q1
$97.3K Buy
11,254
+1,643
+17% +$14.6K ﹤0.01% 4039
2024
Q4
$67K Sell
9,611
-187
-2% -$1.27K ﹤0.01% 4190
2024
Q3
$73.5K Buy
9,798
+163
+2% +$1.38K ﹤0.01% 4178
2024
Q2
$91.5K Buy
9,635
+749
+8% +$7.29K ﹤0.01% 4161
2024
Q1
$80.7K Sell
8,886
-130
-1% -$1.21K ﹤0.01% 4226
2023
Q4
$96.9K Hold
9,016
– – ﹤0.01% 4196
2023
Q3
$106K Sell
9,016
-256
-3% -$4.17K ﹤0.01% 4231
2023
Q2
$195K Buy
9,272
+6,742
+266% +$135K ﹤0.01% 4057
2023
Q1
$48.6K Hold
2,530
– – ﹤0.01% 4527
2022
Q4
$65K Buy
2,530
+212
+9% +$4.98K ﹤0.01% 4520
2022
Q3
$48K Hold
2,318
– – ﹤0.01% 4775
2022
Q2
$32K Sell
2,318
-1,072
-32% -$20.2K ﹤0.01% 4860
2022
Q1
$76K Buy
3,390
+1,032
+44% +$31K ﹤0.01% 4728
2021
Q4
$105K Buy
+2,358
New +$280K ﹤0.01% 4717

Other funds holding INKT

Geode Capital Management's INKT Position: Q3 2026 in Review

Geode Capital Management increased its MiNK Therapeutics (INKT) stake by 20% in Q3 2026, buying an estimated $36.2K and bringing the position to 18,759 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3819.

Geode Capital Management first reported a position in INKT in Q4 2021 and has held it in 20 quarters since. 7 funds tracked by Wall St. Rank hold INKT as of Q3 2026.

  • Geode Capital Management held 18,759 shares of MiNK Therapeutics worth $235K as of Q3 2026.
  • Geode Capital Management bought 3,186 MiNK Therapeutics shares in Q3 2026, an estimated $36.2K.
  • MiNK Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3819 holding.
  • Geode Capital Management first reported a position in MiNK Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • 7 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.